Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Bagossi, P.; Sperka, T.; Feher, A.; Kadas, J.; Zahuczky, G.; Miklossy, G.; Boross, P.; Toezser, J.
    Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites (2005), J. Virol., 79, 4213-4218.
    View publication on PubMedView publication on EuropePMC

Cloned(Commentary)

EC Number Cloned (Comment) Organism
3.4.23.B3 phylogenetic analysis, comparison to other retroviruses, overview equine infectious anemia virus
3.4.23.B5 expression as His-tagged maltose-binding protein fusion enzyme in Escherichia coli, phylogenetic tree Moloney murine leukemia virus
3.4.23.B6 phylogenetic tree Mason-Pfizer monkey virus

Crystallization (Commentary)

EC Number Crystallization (Comment) Organism
3.4.23.B3 crystal structure analysis, structure-sequence comparison, molecular modeling, comparison to other retroviruses, overview equine infectious anemia virus

KM Value [mM]

EC Number KM Value [mM] KM Value Maximum [mM] Substrate Comment Organism Structure
3.4.23.16 additional information
-
 additional information
-
 Human immunodeficiency virus 1
3.4.23.47 additional information
-
 additional information
-
 Human immunodeficiency virus 2

Metals/Ions

EC Number Metals/Ions Comment Organism Structure
3.4.23.B3 NaCl enzyme assay in presence of 2 M NaCl equine infectious anemia virus
3.4.23.B6 NaCl activates at 2 M Mason-Pfizer monkey virus
3.4.23.B9 NaCl activates at 2 M bovine leukemia virus

Molecular Weight [Da]

EC Number Molecular Weight [Da] Molecular Weight Maximum [Da] Comment Organism
3.4.23.B6 12000
-
 x * 12000, isozyme p12 Mason-Pfizer monkey virus

Organism

EC Number Organism UniProt Comment Textmining
3.4.23.B3 equine infectious anemia virus P32542 EIAV, a lenti-retrovirus
-
3.4.23.B5 Moloney murine leukemia virus
-
 MMLV, belongs to the gamma-retrovirus group
-
3.4.23.B6 Mason-Pfizer monkey virus
-
 M-PMV, isozyme p12, belongs to the betaretrovirus group
-
3.4.23.B8 Human T-cell leukemia virus type I
-
-
-
3.4.23.B9 bovine leukemia virus
-
 BLV, belongs to the deltaretrovirus group
-
3.4.23.B11 human foamy virus
-
-
-
3.4.23.16 Human immunodeficiency virus 1 P04587 i.e. HIV-1
-
3.4.23.B17 walleye dermal sarcoma virus
-
-
-
3.4.23.B18 mouse mammary tumor virus
-
-
-
3.4.23.47 Human immunodeficiency virus 2 P04584 i.e. HIV-2
-

Purification (Commentary)

EC Number Purification (Comment) Organism
3.4.23.B5 expression as His-tagged maltose-binding protein fusion enzyme from Escherichia coli, the fusion protein is cleaved off Moloney murine leukemia virus
3.4.23.B6 isozyme p12 Mason-Pfizer monkey virus
3.4.23.B9 from recombinant inclusion bodies bovine leukemia virus
3.4.23.47 purification of chemically synthesized enzyme Human immunodeficiency virus 2

Reaction

EC Number Reaction Comment Organism Reaction ID
3.4.23.B3 Processing at the authentic HIV-1 PR recognition site and release of the mature p17 matrix and the p24 capsid protein, as a result of the cleavage of the -SQNY-/-PIVQ- cleavage site. structure-based molecular modeling of reaction mechanism and substrate binding equine infectious anemia virus
a
3.4.23.B5 processing of viral polyprotein. The retroviral protease is essential for virus replication, by processing of viral Gag and Gag-Pol polyproteins structure-based molecular modeling of reaction mechanism and substrate binding Moloney murine leukemia virus
a

Renatured (Commentary)

EC Number Renatured (Comment) Organism
3.4.23.47 renaturation of purified chemically synthesized enzyme Human immunodeficiency virus 2

Specific Activity [micromol/min/mg]

EC Number Specific Activity Minimum [µmol/min/mg] Specific Activity Maximum [µmol/min/mg] Comment Organism
3.4.23.B6 additional information
-
-
 Mason-Pfizer monkey virus

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
3.4.23.B3 additional information P2 position preference with peptide substrate Val-Ser-Gln-Xaa-Tyr-Pro-Ile-Val-Gln, comparison to other retroviruses, overview equine infectious anemia virus ?
-
 ?
3.4.23.B3 Val-Ser-Gln-Ala-Tyr-Pro-Ile-Val-Gln + H2O good substrate equine infectious anemia virus Val-Ser-Gln-Ala-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B3 Val-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln + H2O
-
 equine infectious anemia virus Val-Ser-Gln-Asn-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B3 Val-Ser-Gln-Cys-Tyr-Pro-Ile-Val-Gln + H2O best peptide substrate equine infectious anemia virus Val-Ser-Gln-Cys-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B3 Val-Ser-Gln-Gly-Tyr-Pro-Ile-Val-Gln + H2O low activity equine infectious anemia virus Val-Ser-Gln-Gly-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B3 Val-Ser-Gln-Ile-Tyr-Pro-Ile-Val-Gln + H2O
-
 equine infectious anemia virus Val-Ser-Gln-Ile-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B3 Val-Ser-Gln-Leu-Tyr-Pro-Ile-Val-Gln + H2O
-
 equine infectious anemia virus Val-Ser-Gln-Leu-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B3 Val-Ser-Gln-Phe-Tyr-Pro-Ile-Val-Gln + H2O low activity equine infectious anemia virus Val-Ser-Gln-Phe-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B3 Val-Ser-Gln-Thr-Tyr-Pro-Ile-Val-Gln + H2O
-
 equine infectious anemia virus Val-Ser-Gln-Thr-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B3 Val-Ser-Gln-Val-Tyr-Pro-Ile-Val-Gln + H2O
-
 equine infectious anemia virus Val-Ser-Gln-Val-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B5 additional information study of influence of the P2 position residue on cleavage site specificity, overview Moloney murine leukemia virus ?
-
 ?
3.4.23.B5 Val-Ser-Gln-Ala-Tyr-Pro-Ile-Val-Gln + H2O
-
 Moloney murine leukemia virus Val-Ser-Gln-Ala-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B5 Val-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln + H2O
-
 Moloney murine leukemia virus Val-Ser-Gln-Asn-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B5 Val-Ser-Gln-Cys-Tyr-Pro-Ile-Val-Gln + H2O
-
 Moloney murine leukemia virus Val-Ser-Gln-Cys-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B5 Val-Ser-Gln-Gly-Tyr-Pro-Ile-Val-Gln + H2O
-
 Moloney murine leukemia virus Val-Ser-Gln-Gly-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B5 Val-Ser-Gln-Ile-Tyr-Pro-Ile-Val-Gln + H2O
-
 Moloney murine leukemia virus Val-Ser-Gln-Ile-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B5 Val-Ser-Gln-Leu-Tyr-Pro-Ile-Val-Gln + H2O
-
 Moloney murine leukemia virus Val-Ser-Gln-Leu-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B5 Val-Ser-Gln-Phe-Tyr-Pro-Ile-Val-Gln + H2O
-
 Moloney murine leukemia virus Val-Ser-Gln-Phe-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B5 Val-Ser-Gln-Thr-Tyr-Pro-Ile-Val-Gln + H2O
-
 Moloney murine leukemia virus Val-Ser-Gln-Thr-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B5 Val-Ser-Gln-Val-Tyr-Pro-Ile-Val-Gln + H2O
-
 Moloney murine leukemia virus Val-Ser-Gln-Val-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B6 additional information study of influence of the P2 position residue on cleavage site specificity of isozyme p12, overview Mason-Pfizer monkey virus ?
-
 ?
3.4.23.B6 PKDIFPVTET + H2O a p12/CA cleavage site Mason-Pfizer monkey virus PKDIF + PVTET
-
 ?
3.4.23.B6 Val-Ser-Gln-Ala-Tyr-Pro-Ile-Val-Gln + H2O
-
 Mason-Pfizer monkey virus Val-Ser-Gln-Ala-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B6 Val-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln + H2O
-
 Mason-Pfizer monkey virus Val-Ser-Gln-Asn-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B6 Val-Ser-Gln-Cys-Tyr-Pro-Ile-Val-Gln + H2O
-
 Mason-Pfizer monkey virus Val-Ser-Gln-Cys-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B6 Val-Ser-Gln-Gly-Tyr-Pro-Ile-Val-Gln + H2O
-
 Mason-Pfizer monkey virus Val-Ser-Gln-Gly-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B6 Val-Ser-Gln-Ile-Tyr-Pro-Ile-Val-Gln + H2O
-
 Mason-Pfizer monkey virus Val-Ser-Gln-Ile-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B6 Val-Ser-Gln-Leu-Tyr-Pro-Ile-Val-Gln + H2O
-
 Mason-Pfizer monkey virus Val-Ser-Gln-Leu-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B6 Val-Ser-Gln-Phe-Tyr-Pro-Ile-Val-Gln + H2O low activity Mason-Pfizer monkey virus Val-Ser-Gln-Phe-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B6 Val-Ser-Gln-Thr-Tyr-Pro-Ile-Val-Gln + H2O
-
 Mason-Pfizer monkey virus Val-Ser-Gln-Thr-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B6 Val-Ser-Gln-Val-Tyr-Pro-Ile-Val-Gln + H2O
-
 Mason-Pfizer monkey virus Val-Ser-Gln-Val-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B8 VSQCYPIVG + H2O peptides with an Ile or Leu at position P2 are the best substrate, lower activity with Val or Cys at position P2, no activity with Ala, Phe, Gly Thr or An at position P2 Human T-cell leukemia virus type I VSQCY + PIVG
-
 ?
3.4.23.B8 VSQIYPIVG + H2O peptides with an Ile or Leu at position P2 are the best substrate, lower activity with Val or Cys at position P2, no activity with Ala, Phe, Gly Thr or An at position P2 Human T-cell leukemia virus type I VSQIY + PIVG
-
 ?
3.4.23.B8 VSQLYPIVG + H2O peptides with an Ile or Leu at position P2 are the best substrate, lower activity with Val or Cys at position P2, no activity with Ala, Phe, Gly Thr or An at position P2 Human T-cell leukemia virus type I VSQLY + PIVG
-
 ?
3.4.23.B8 VSQVYPIVG + H2O peptides with an Ile or Leu at position P2 are the best substrate, lower activity with Val or Cys at position P2, no activity with Ala, Phe, Gly Thr or An at position P2 Human T-cell leukemia virus type I VSQVY + PIVG
-
 ?
3.4.23.B9 additional information study of influence of the P2 position residue on cleavage site specificity, overview bovine leukemia virus ?
-
 ?
3.4.23.B9 Val-Ser-Gln-Ala-Tyr-Pro-Ile-Val-Gln + H2O
-
 bovine leukemia virus Val-Ser-Gln-Ala-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B9 Val-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln + H2O
-
 bovine leukemia virus Val-Ser-Gln-Asn-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B9 Val-Ser-Gln-Cys-Tyr-Pro-Ile-Val-Gln + H2O
-
 bovine leukemia virus Val-Ser-Gln-Cys-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B9 Val-Ser-Gln-Gly-Tyr-Pro-Ile-Val-Gln + H2O
-
 bovine leukemia virus Val-Ser-Gln-Gly-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B9 Val-Ser-Gln-Ile-Tyr-Pro-Ile-Val-Gln + H2O
-
 bovine leukemia virus Val-Ser-Gln-Ile-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B9 Val-Ser-Gln-Leu-Tyr-Pro-Ile-Val-Gln + H2O
-
 bovine leukemia virus Val-Ser-Gln-Leu-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B9 Val-Ser-Gln-Phe-Tyr-Pro-Ile-Val-Gln + H2O
-
 bovine leukemia virus Val-Ser-Gln-Phe-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B9 Val-Ser-Gln-Thr-Tyr-Pro-Ile-Val-Gln + H2O
-
 bovine leukemia virus Val-Ser-Gln-Thr-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B9 Val-Ser-Gln-Val-Tyr-Pro-Ile-Val-Gln + H2O
-
 bovine leukemia virus Val-Ser-Gln-Val-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B11 VSQAYPIVG + H2O X: Cys and Ala are preferred at P2 position human foamy virus VSQAY + PIVG
-
 ?
3.4.23.B11 VSQCYPIVG + H2O X: Cys and Ala are preferred at P2 position human foamy virus VSQCY + PIVG
-
 ?
3.4.23.16 additional information amino acid preferences for the critical P2' substrate binding subsite in type 1 cleavage sites, molecular modeling and phylogenetic comparison, overview Human immunodeficiency virus 1 ?
-
 ?
3.4.23.16 Val-Ser-Gln-Ala-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 1 Val-Ser-Gln-Ala-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.16 Val-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 1 Val-Ser-Gln-Asn-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.16 Val-Ser-Gln-Cys-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 1 Val-Ser-Gln-Cys-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.16 Val-Ser-Gln-Gly-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 1 Val-Ser-Gln-Gly-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.16 Val-Ser-Gln-Ile-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 1 Val-Ser-Gln-Ile-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.16 Val-Ser-Gln-Leu-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 1 Val-Ser-Gln-Leu-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.16 Val-Ser-Gln-Phe-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 1 Val-Ser-Gln-Phe-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.16 Val-Ser-Gln-Thr-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 1 Val-Ser-Gln-Thr-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.16 Val-Ser-Gln-Val-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 1 Val-Ser-Gln-Val-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.B17 VSQAYPIVG + H2O peptides with an Asn, Cys or Leu at position P2 are the best substrate, lower activity with Ala or Ile at position P2, no activity with Gly walleye dermal sarcoma virus VSQAY + PIVG
-
 ?
3.4.23.B17 VSQCYPIVG + H2O peptides with an Asn, Cys or Leu at position P2 are the best substrate, lower activity with Ala or Ile at position P2, no activity with Gly walleye dermal sarcoma virus VSQCY + PIVG
-
 ?
3.4.23.B17 VSQIYPIVG + H2O peptides with an Asn, Cys or Leu at position P2 are the best substrate, lower activity with Ala or Ile at position P2, no activity with Gly walleye dermal sarcoma virus VSQIY + PIVG
-
 ?
3.4.23.B17 VSQLYPIVG + H2O peptides with an Asn, Cys or Leu at position P2 are the best substrate, lower activity with Ala or Ile at position P2, no activity with Gly walleye dermal sarcoma virus VSQLY + PIVG
-
 ?
3.4.23.B17 VSQNYPIVG + H2O peptides with an Asn, Cys or Leu at position P2 are the best substrate, lower activity with Ala or Ile at position P2, no activity with Gly walleye dermal sarcoma virus VSQNY + PIVG
-
 ?
3.4.23.B18 VSQCYPIVG + H2O peptides with an Ile at position P2 are the best substrate, lower activity with Cys or Leu at position P2 mouse mammary tumor virus VSQCY + PIVG
-
 ?
3.4.23.B18 VSQIYPIVG + H2O peptides with an Ile at position P2 are the best substrate, lower activity with Cys or Leu at position P2 mouse mammary tumor virus VSQIY + PIVG
-
 ?
3.4.23.B18 VSQLYPIVG + H2O peptides with an Ile at position P2 are the best substrate, lower activity with Cys or Leu at position P2 mouse mammary tumor virus VSQLY + PIVG
-
 ?
3.4.23.47 additional information amino acid preferences for the critical P2' substrate binding subsite in type 1 cleavage sites, molecular modeling and phylogenetic comparison, overview Human immunodeficiency virus 2 ?
-
 ?
3.4.23.47 Val-Ser-Gln-Ala-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 2 Val-Ser-Gln-Ala-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.47 Val-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 2 Val-Ser-Gln-Asn-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.47 Val-Ser-Gln-Cys-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 2 Val-Ser-Gln-Cys-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.47 Val-Ser-Gln-Gly-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 2 Val-Ser-Gln-Gly-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.47 Val-Ser-Gln-Ile-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 2 Val-Ser-Gln-Ile-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.47 Val-Ser-Gln-Leu-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 2 Val-Ser-Gln-Leu-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.47 Val-Ser-Gln-Phe-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 2 Val-Ser-Gln-Phe-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.47 Val-Ser-Gln-Thr-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 2 Val-Ser-Gln-Thr-Tyr + Pro-Ile-Val-Gln
-
 ?
3.4.23.47 Val-Ser-Gln-Val-Tyr-Pro-Ile-Val-Gln + H2O
-
 Human immunodeficiency virus 2 Val-Ser-Gln-Val-Tyr + Pro-Ile-Val-Gln
-
 ?

Subunits

EC Number Subunits Comment Organism
3.4.23.B3 More structure molecular modeling, S2 subsite sequence comparison equine infectious anemia virus
3.4.23.B5 More structure molecular modeling, S2 subsite sequence comparison Moloney murine leukemia virus
3.4.23.B6 ? x * 12000, isozyme p12 Mason-Pfizer monkey virus
3.4.23.B6 More isozyme p12: structure molecular modeling, S2 subsite sequence comparison Mason-Pfizer monkey virus
3.4.23.B9 More structure molecular modeling, S2 subsite sequence comparison bovine leukemia virus

Synonyms

EC Number Synonyms Comment Organism
3.4.23.B3 EIAV retropepsin
-
 equine infectious anemia virus
3.4.23.B3 equine infectious anemia virus retropepsin
-
 equine infectious anemia virus
3.4.23.B5 MMLV protease
-
 Moloney murine leukemia virus
3.4.23.B6 MPMV protease
-
 Mason-Pfizer monkey virus
3.4.23.B8 HTLV-1 protease
-
 Human T-cell leukemia virus type I
3.4.23.B9 BLV PR
-
 bovine leukemia virus
3.4.23.B9 BLV protease
-
 bovine leukemia virus
3.4.23.B11 HFV PR
-
 human foamy virus
3.4.23.16 HIV-1 protease
-
 Human immunodeficiency virus 1
3.4.23.B17 WDSV PR
-
 walleye dermal sarcoma virus
3.4.23.B18 MMTV PR
-
 mouse mammary tumor virus
3.4.23.47 HIV-2 protease
-
 Human immunodeficiency virus 2

Temperature Optimum [°C]

EC Number Temperature Optimum [°C] Temperature Optimum Maximum [°C] Comment Organism
3.4.23.B3 37
-
 assay at equine infectious anemia virus
3.4.23.B5 37
-
 assay at Moloney murine leukemia virus
3.4.23.B6 37
-
 assay at Mason-Pfizer monkey virus
3.4.23.B9 37
-
 assay at bovine leukemia virus
3.4.23.16 37
-
 assay at Human immunodeficiency virus 1
3.4.23.47 37
-
 assay at Human immunodeficiency virus 2

pH Optimum

EC Number pH Optimum Minimum pH Optimum Maximum Comment Organism
3.4.23.B3 5.6
-
 assay at equine infectious anemia virus
3.4.23.B5 5.6
-
 assay at Moloney murine leukemia virus
3.4.23.B6 5.6
-
 assay at Mason-Pfizer monkey virus
3.4.23.B9 5.6
-
 assay at bovine leukemia virus
3.4.23.16 5.6
-
 assay at Human immunodeficiency virus 1
3.4.23.47 5.6
-
 assay at Human immunodeficiency virus 2